1,024 material Form 8-K filings that 799 companies we cover made with the SEC in August 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Brown & Brown closed its acquisition of RSC Topco, the holding company for Accession Risk Management Group, on August 1, 2025, for an aggregate purchase price of $9.825 billion, subject to post-closing adjustments. Approximately $4.7 billion of the net merger consideration went to RSC equityholders, paid as about $3.5 billion in cash and about $1.2 billion in newly issued Brown & Brown common stock. The deal is a large acquisition, and the new shares are subject to multi-year lock-up restrictions.
Acquisition closed August 1, 2025, with an aggregate purchase price of $9.825 billion, subject to customary post-closing adjustments
Net merger consideration of approximately $4.7 billion: about $3.5 billion in cash and about $1.2 billion in common stock
Stock consideration was priced using the $110.57 per share closing price on June 6, 2025, and was issued in an unregistered private placement
Some recipients agreed to a five-year lock-up, with 20% of shares released on the second, third and fourth anniversaries and 40% on the fifth; financial statements and pro forma information will be filed by amendment
Southside Bancshares said Chief Operating Officer Brian K. McCabe will retire effective November 14, 2025, after working at the bank in operational roles since 1983 and as COO since 2017. The company expects to appoint Mitchell Craddock, currently Executive Vice President and Associate Chief Operations Officer, as COO before McCabe's retirement date.
Brian K. McCabe notified the company on August 4, 2025 of his decision to retire, effective November 14, 2025
McCabe has been COO since 2017 and has worked at the bank since 1983; he remains an advisory director of the bank
Mitchell Craddock, 45, joined the bank in August 2024 and previously spent 2011 to 2024 at digital banking firm Q2
The board anticipates appointing Craddock as COO prior to November 14, 2025
Leidos reported second-quarter fiscal 2025 revenue of $4.3 billion, up 3% from a year earlier, and net income of $393 million, or $3.01 per diluted share, up 27% in EPS. The company raised its full-year 2025 guidance for revenue, adjusted EBITDA margin, non-GAAP diluted EPS and operating cash flow, which is a positive signal for shareholders.
Q2 revenue of $4,253 million versus $4,132 million a year earlier; diluted EPS $3.01 versus $2.37
Non-GAAP diluted EPS of $3.21, up 22%; included a $25 million insurance reimbursement for prior-period legal costs
FY25 non-GAAP diluted EPS guidance raised to $11.15-$11.45 from $10.35-$10.75
Quarterly dividend of $0.40 per share declared August 1, 2025, payable September 30, 2025
Archrock reported second-quarter 2025 revenue of $383.2 million, up from $270.5 million a year earlier, and net income of $63.4 million, or $0.36 per share, compared with $34.4 million and $0.22 in the second quarter of 2024. The company also raised its full-year 2025 adjusted EBITDA guidance, citing continued outperformance, which signals higher expected earnings for shareholders.
Q2 2025 adjusted EBITDA was $212.7 million, compared with $129.7 million in Q2 2024.
Q2 2025 adjusted EPS was $0.39, compared with $0.23 in Q2 2024.
The quarterly dividend was $0.21 per share, about 27% higher than Q2 2024, with dividend coverage of 3.4x.
Archrock repurchased 1,226,954 shares for about $28.8 million in Q2 and had $58.9 million of repurchase capacity left as of June 30, 2025.
JBT Marel reported second quarter 2025 revenue of $935 million, up from $402 million a year earlier, after the Marel transaction closed at the beginning of 2025. Income from continuing operations fell to $3 million, or $0.07 diluted EPS, from $31 million a year earlier, and the company re-established full year 2025 guidance, including revenue of $3,675 million to $3,725 million and adjusted EPS of $5.45 to $6.15.
Q2 2025 revenue was $935 million versus $402 million in Q2 2024; adjusted EBITDA was $156 million versus $64 million.
Income from continuing operations was $3 million ($0.07 diluted EPS) versus $31 million ($0.95 diluted EPS) a year earlier; adjusted EPS was $1.49.
Full year 2025 guidance: revenue $3,675 million to $3,725 million, GAAP EPS ($1.90) to ($1.20), adjusted EPS $5.45 to $6.15.
The filing cites an $11 million loss on investment from a joint-venture impairment and $20 million in M&A related costs in the quarter.
Atlas Energy Solutions reported second-quarter 2025 revenue of $288.7 million, down 3.0% from the first quarter, and a net loss of $5.6 million, compared with net income of $1.2 million in the prior quarter. The company expects a modest decline in both consolidated revenue and Adjusted EBITDA in the third quarter, which weighs on the outlook for shareholders, though the quarterly dividend of $0.25 per share was maintained.
Q2 2025 revenue was $288.7 million, versus $297.6 million in Q1 2025 and $287.5 million in Q2 2024.
Net loss was $5.6 million, or $(0.04) per share, compared with net income of $1.2 million in Q1 2025.
Adjusted EBITDA was $70.5 million, down from $74.3 million in Q1 2025.
Third-quarter guidance calls for a modest decline in consolidated revenue and Adjusted EBITDA, with higher proppant volume offset by lower average prices and short-fall payments.
BWX Technologies reported second quarter 2025 revenue of $764.0 million, up 12% from a year earlier, and GAAP diluted EPS of $0.85, up from $0.79. The company raised its 2025 guidance for revenue, adjusted EBITDA, non-GAAP EPS and free cash flow, citing strong year-to-date results and bookings, which supports the outlook for shareholders.
Q2 2025 revenue $764.0 million, up 12%; Government Operations $589.0 million, Commercial Operations $176.1 million
GAAP diluted EPS $0.85 vs. $0.79 a year earlier; non-GAAP EPS $1.02 vs. $0.82
Raised 2025 guidance: revenue to about $3,100 million from about $3,000 million; non-GAAP EPS to $3.65-$3.75 from $3.40-$3.55
Record backlog of $6.0 billion, up 70.2% year-over-year; Kinectrics acquisition closed May 20, 2025
Tidewater reported second-quarter 2025 revenue of $341.4 million and net income of $72.9 million, or $1.46 per diluted share, compared with $50.4 million, or $0.94 per share, a year earlier. The net income includes a one-time, non-cash $27.0 million increase from reversing a valuation allowance on U.S. net operating losses, and the company reiterated its 2025 revenue and gross margin guidance. The Board also approved a share repurchase program of up to $500.0 million, which the company may modify, suspend or discontinue at any time.
Q2 2025 revenue of $341.4 million, up 0.6% from $339.2 million in Q2 2024.
Net income attributable to Tidewater of $72.9 million ($1.46 diluted per share), versus $50.4 million ($0.94) a year earlier, including a one-time, non-cash $27.0 million benefit.
Board authorized a share repurchase program of up to $500.0 million; the company is not obligated to buy any specific number of shares.
2025 revenue guidance of $1.32 billion to $1.38 billion and gross margin guidance of 48% to 50% were reiterated.
Centerspace reported a second-quarter 2025 net loss of $0.87 per diluted share, compared with $0.19 a year earlier, after a $14.5 million real estate impairment. Revenue rose 5.4% to $68.5 million and Core FFO per diluted share edged up to $1.28 from $1.27, but the company narrowed and lowered its 2025 FFO per diluted share outlook to $4.70 to $4.83 from $4.73 to $4.97. The Board also authorized a share repurchase program of up to $100 million through July 31, 2026.
Q2 2025 net loss was $0.87 per diluted share versus $0.19 in Q2 2024; six-month net loss was $1.09 versus $0.56.
Core FFO was $1.28 per diluted share versus $1.27; same-store NOI rose 2.9% year over year.
2025 FFO per diluted share outlook is $4.70 to $4.83, down from $4.73 to $4.97; Core FFO outlook is $4.88 to $5.00, down from $4.86 to $5.10.
Repurchase program of up to $100 million of common shares was effective July 31, 2025, with no obligation to buy any specific number of shares.
Crown Castle appointed Christian Hillabrant, former CEO of Vantage Towers AG, as President and CEO, effective September 15, 2025, replacing Interim CEO Daniel Schlanger, who will become Chief Transformation Officer. The filing also sets out a compensation package including a $1,000,000 base salary and make-whole awards, and it does not report any financial results.
Hillabrant starts as CEO on an expected September 15, 2025, and is expected to join the Board at that time.
Base salary for 2025 is $1,000,000, prorated from the start date; one-time make-whole bonus of $800,000 and make-whole RSUs of about $7,000,000.
Target annual incentive is 200% of base salary; 2025 annual RSUs of about $5,250,000, with a $10,500,000 target grant value expected for 2026.
Schlanger will oversee completion of the sale of the small cells and fiber solutions businesses, expected to close in the first half of 2026.
HealthStream reported second-quarter 2025 revenue of $74.4 million, up 4.0% and a company record, with net income of $5.4 million, up 29.3%, and diluted EPS of $0.18 versus $0.14 a year earlier. The company raised its 2025 net income guidance to $19.5 million-$22.4 million from $18.6 million-$21.0 million, and the board declared a $0.031 quarterly dividend.
Q2 2025 revenue was $74.4 million, up from $71.6 million in Q2 2024, a company record for quarterly revenue.
Q2 2025 net income was $5.4 million and diluted EPS was $0.18, compared with $4.2 million and $0.14 in Q2 2024.
Full-year 2025 net income guidance was raised to $19.5 million-$22.4 million from $18.6 million-$21.0 million; revenue guidance is $297.5 million-$303.5 million.
The board declared a $0.031 per share dividend payable August 29, 2025, to holders of record on August 18, 2025; the $25.0 million buyback program was completed in July.
New Jersey Resources reported a fiscal third-quarter GAAP net loss of $15.1 million, or $(0.15) per share, wider than the $11.6 million loss a year earlier. Its non-GAAP net financial earnings (NFE) turned positive at $6.2 million, or $0.06 per share, and the company raised the low end of its fiscal 2025 NFE per share guidance by $0.05, to $3.20 to $3.30.
Q3 GAAP net loss of $15.1 million, or $(0.15) per share, versus a net loss of $11.6 million, or $(0.12) per share, in Q3 fiscal 2024
Q3 net financial earnings of $6.2 million, or $0.06 per share, versus a net financial loss of $8.9 million, or $(0.09) per share, a year earlier
Fiscal 2025 NFE per share guidance low end raised $0.05, from $3.15 to $3.30 to $3.20 to $3.30
Q3 total operating revenues of $298.9 million, up from $275.6 million; nine-month net income of $320.6 million, or $3.20 per share
Ingevity reported second quarter 2025 net sales of $365.1 million, down 7%, and a net loss of $146.5 million, or $4.02 per diluted share, which included a $183.8 million non-cash goodwill impairment tied to the Advanced Polymer Technologies segment. Adjusted earnings rose 39% to $51.1 million, and the company raised the low end of its full-year adjusted EBITDA guidance to a range of $390 million to $415 million while maintaining its sales guidance of $1.25 billion to $1.40 billion.
Q2 net sales were $365.1 million, down 7%, mainly due to lower Performance Chemicals sales
Net loss of $146.5 million and diluted loss of $4.02 per share, including a $183.8 million goodwill impairment
Adjusted earnings rose 39% to $51.1 million; diluted adjusted EPS was $1.39, up 38%
Full-year 2025 adjusted EBITDA guidance is $390 million to $415 million; sales guidance remains $1.25 billion to $1.40 billion
Primoris Services reported second-quarter 2025 revenue of $1,890.7 million, up 20.9% from a year earlier, and diluted EPS of $1.54 versus $0.91. The company raised its full-year 2025 diluted EPS guidance to $4.40 to $4.60 and its adjusted EPS guidance to $4.90 to $5.10, and declared a $0.08 per share dividend.
Q2 2025 revenue was $1,890.7 million, up $327.0 million, or 20.9%, from Q2 2024.
Diluted EPS was $1.54 versus $0.91; adjusted diluted EPS was $1.68 versus $1.04.
Full-year 2025 diluted EPS guidance was raised to $4.40 to $4.60; adjusted EPS guidance to $4.90 to $5.10.
Board declared a $0.08 per share cash dividend, record date September 30, 2025, payable on or about October 15, 2025.
The Andersons completed its purchase of Marathon's 49.9% stake in The Andersons Marathon Holdings LLC for $425 million, including $40 million of working capital, on July 31, 2025, giving it full ownership of four ethanol plants with 500 million gallons of annual capacity. In second quarter results, net income attributable to the company fell to $7.9 million, or $0.23 per diluted share, from $36.0 million, or $1.05, a year earlier, even as sales and merchandising revenues rose to $3.1 billion from $2.8 billion. The company funded the deal with cash on hand and existing credit facilities, and said it expects immediate accretion to earnings per share.
Q2 2025 net income attributable to The Andersons was $7.9 million, or $0.23 per diluted share, versus $36.0 million, or $1.05, in Q2 2024.
Q2 2025 sales and merchandising revenues were $3.1 billion, up from $2.8 billion in Q2 2024.
Acquisition price was $425 million, including $40 million of working capital; the transaction closed July 31, 2025.
Full-year adjusted effective tax rate is now expected to be approximately 22% to 25%.
Encompass Health reported second-quarter 2025 net operating revenue of $1,457.7 million, up 12.0% from $1,301.2 million a year earlier, and diluted earnings per share from continuing operations of $1.40, up from $1.13. The company raised its full-year 2025 guidance for net operating revenue, adjusted EBITDA and adjusted earnings per share, which gives shareholders a higher outlook for the year.
Q2 2025 net operating revenue was $1,457.7 million, up 12.0%; diluted EPS from continuing operations was $1.40 versus $1.13.
Adjusted EPS was $1.40 versus $1.11 a year earlier; adjusted EBITDA was $318.6 million, up 17.2%.
Full-year 2025 adjusted EPS guidance rose to $5.12 to $5.34 from $4.85 to $5.10; net operating revenue guidance rose to $5,880 to $5,980 million.
Management will discuss results on an earnings call at 10:00 a.m. Eastern Time on August 5, 2025.
Axon reported second-quarter 2025 revenue of $669 million, up 33% year over year, and raised its full-year 2025 revenue outlook to $2.65 billion to $2.73 billion from $2.60 billion to $2.70 billion. Net income was $36 million, but the company posted a $1 million operating loss driven by $139 million of stock-based compensation expense, and total gross margin fell 40 basis points year over year to 60.4%. For shareholders, the higher revenue and raised guidance are the main headline measures, while stock-based compensation weighed on reported operating results.
Q2 2025 revenue of $669 million rose 33% year over year; Software & Services revenue rose 39% to $292 million.
Full-year 2025 revenue outlook raised to $2.65 billion to $2.73 billion, from $2.60 billion to $2.70 billion previously.
Full-year 2025 Adjusted EBITDA outlook raised to $665 million to $685 million, from $650 million to $675 million previously.
Q2 net income was $36 million, or $0.44 per diluted share; operating loss of $1 million included $139 million of stock-based compensation expense.
Williams reported second-quarter 2025 GAAP net income of $546 million, or $0.45 per diluted share, compared with $401 million, or $0.33 per share, a year earlier. The company raised the midpoint of its 2025 Adjusted EBITDA guidance by $50 million to $7.75 billion, citing Transco expansion projects and new Gulf volumes. For shareholders, the higher guidance and a dividend increase to $2.00 for 2025 indicate improved expected earnings and returns.
GAAP net income was $546 million, or $0.45 per diluted share, versus $401 million, or $0.33, in second-quarter 2024.
Adjusted EBITDA was $1.808 billion, up $141 million or 8% from second-quarter 2024.
2025 Adjusted EBITDA guidance midpoint raised by $50 million to $7.75 billion, within a range of $7.6 billion to $7.9 billion.
Dividend increased 5.3% on an annualized basis to $2.00 in 2025 from $1.90 in 2024.
Equity Residential (NYSE: EQR) reported second-quarter 2025 diluted EPS of $0.50, up from $0.47, and FFO of $0.98 per share, up from $0.94. It raised the midpoints of full-year FFO and Normalized FFO guidance but lowered full-year EPS guidance to $2.96 to $3.02 from $3.00 to $3.10. The filing names Equity Residential, not VIVMARK RESIDENTIAL as stated in the request.
Q2 2025 diluted EPS $0.50 vs. $0.47; FFO $0.98 vs. $0.94; Normalized FFO $0.99 vs. $0.97 per share
Six-month diluted EPS of $1.18 vs. $1.24 a year earlier, down 4.8%
Full-year 2025 FFO guidance raised to $4.03-$4.09 from $3.87-$3.97; EPS guidance cut to $2.96-$3.02 from $3.00-$3.10
Q2 same store revenues up 2.7% and same store NOI up 2.3% vs. Q2 2024; eight Atlanta properties acquired for approximately $533.8 million
Sterling Infrastructure reported second quarter 2025 revenue of $614.5 million, up 21% excluding the deconsolidated RHB joint venture, and net income of $71.0 million, or $2.31 per diluted share, up 37% and 38%. The company raised its full year 2025 guidance, which excludes any contribution from the pending CEC Facilities Group acquisition.
Q2 net income $71.0 million, or $2.31 per diluted share, up 37% and 38% from the prior year quarter
Adjusted diluted EPS of $2.69, up 41%; adjusted EBITDA of $125.6 million, up 35%
Full year 2025 guidance: revenue of $2.10 billion to $2.15 billion and diluted EPS of $7.87 to $8.13
Building Solutions revenue declined 1%; the company expects soft market conditions to persist in the near term
LTC Properties reported second-quarter 2025 revenue of $60.2 million, up from $50.1 million a year earlier, mainly from converting Anthem and New Perspective triple-net properties into its SHOP senior housing portfolio. Net income available to common stockholders fell to $14.9 million, or $0.32 per diluted share, from $19.2 million, or $0.44, due to higher transaction costs and general and administrative expenses. The company raised 2025 guidance to reflect $400.0 million of completed and anticipated near-term investments.
Q2 2025 total revenues were $60.2 million, compared with $50.1 million in Q2 2024.
Diluted earnings per share were $0.32, compared with $0.44; diluted Core FFO per share was $0.68, compared with $0.67.
2025 GAAP net income guidance rose to $3.45 to $3.48 per share, from $3.38 to $3.42.
Diluted Core FFO guidance rose to $2.67 to $2.71 per share, from $2.65 to $2.69.
Allison Transmission reported second-quarter 2025 net sales of $814 million, essentially flat from $816 million a year earlier, while net income rose 4% to $195 million. The company also revised its full-year 2025 guidance, citing current end-market conditions, acquisition-related expenses and expected favorable cash income tax impacts from the One Big Beautiful Bill Act. Shareholders also get a view of the pending $2.7 billion acquisition of Dana's Off-Highway business, which is expected to close in late Q4 2025.
Q2 2025 diluted EPS was $2.29, up from $2.13 in Q2 2024; net income was $195 million, up from $187 million.
Q2 Adjusted EBITDA was $313 million, up from $301 million, and Adjusted EBITDA margin was 38.5%.
Revised 2025 guidance: net sales $3,075 to $3,175 million, net income $640 to $680 million, Adjusted EBITDA $1,130 to $1,180 million.
Pending Dana Off-Highway acquisition for approximately $2.7 billion, expected to close late in Q4 2025; Q2 acquisition-related expenses were $15 million.
AECOM reported fiscal third-quarter 2025 results for the quarter ended June 30, 2025, with revenue of $4.18 billion, up 0.7%, and net service revenue of $1.94 billion, up 6%. The company raised its fiscal 2025 guidance for adjusted EBITDA, adjusted EPS, and margins, which points to higher expected earnings for shareholders.
Adjusted EPS was $1.34, up 16%; diluted EPS from continuing operations was $1.31, up 38%
Net income attributable to AECOM was $131 million, down 2.5%, including a $43.9 million loss from discontinued operations
Fiscal 2025 adjusted EPS guidance raised to $5.20 to $5.30; adjusted EBITDA guidance set at $1,190 million to $1,210 million
Free cash flow was $262 million in the quarter; year-to-date free cash flow rose 27% to $551 million
Mueller Water Products reported fiscal third-quarter results for the quarter ended June 30, 2025, with net sales up 6.6% to $380.3 million and diluted earnings per share of $0.33, compared with $0.30 a year earlier. The company raised its fiscal 2025 guidance for net sales and adjusted EBITDA, which points to higher expected full-year results for shareholders, though nine-month free cash flow declined.
Net sales rose 6.6% to $380.3 million; net income was $52.5 million and diluted EPS was $0.33, versus $0.30 a year earlier
Adjusted EBITDA was $86.4 million, up 1.4%, with adjusted EBITDA margin of 22.7% versus 23.9%
Fiscal 2025 guidance raised to net sales of $1,405 million to $1,415 million and adjusted EBITDA of $318 million to $322 million
Nine-month free cash flow was $103.0 million, down from $121.5 million; the company repurchased $10.0 million of stock in the quarter
Palomar Holdings reported second quarter 2025 net income of $46.5 million, or $1.68 per diluted share, up from $25.7 million, or $1.00 per share, a year earlier. It also raised its full-year 2025 adjusted net income outlook to $198 million to $208 million and approved a share repurchase program of up to $150 million through July 31, 2027.
Q2 2025 gross written premiums rose 28.8% to $496.3 million; adjusted net income rose 51.8% to $48.5 million ($1.76 per diluted share).
Combined ratio improved to 78.8% from 79.1%; adjusted return on equity was 23.7%, down from 24.7% a year earlier.
Full-year 2025 adjusted net income outlook raised to $198 million to $208 million from $195 million to $205 million.
Board approved a repurchase program of up to $150 million of common stock, effective July 31, 2025, running through July 31, 2027.
Ichor Holdings announced that CEO Jeffrey Andreson and the Board agreed to a CEO transition plan, and the Board will engage a search firm to find a successor. Andreson stays as CEO until a successor is appointed, then serves in an advisory role through August 31, 2026, with his pay and equity terms set by a Transition Agreement.
Transition Agreement effective August 3, 2025; the company announced the plan in a press release on August 4, 2025
Andreson remains CEO and a Board member until a Successor CEO is appointed, then serves as an advisor until August 31, 2026
During the transition period, Andreson receives a base salary of $20,000 per month and is not eligible for a 2026 annual bonus or new equity grants
The filing states the transition was not the result of any disagreement with the company on its operations, policies, or practices
Diamondback Energy reported second quarter 2025 net income attributable to the company of $699 million, or $2.38 per diluted share, down from $837 million, or $4.66 per share, a year earlier, even though total revenues rose to $3.678 billion from $2.483 billion. The company raised its full-year oil production range to 485 - 492 MBO/d and lowered its 2025 cash capital expenditure forecast to $3.4 - $3.6 billion, and its board raised the share repurchase authorization by $2.0 billion to $8.0 billion.
Q2 2025 net income attributable to Diamondback was $699 million, or $2.38 per diluted share, versus $837 million, or $4.66 per share, in Q2 2024; adjusted net income was $785 million, or $2.67 per diluted share.
Total revenues were $3.678 billion, compared with $2.483 billion in Q2 2024.
2025 cash capital expenditure guidance was lowered to $3.4 - $3.6 billion, and 2025 oil production guidance was narrowed to 485 - 492 MBO/d.
The board approved a $2.0 billion increase in the share repurchase authorization to $8.0 billion on July 31, 2025, with about $3.5 billion remaining; the Q2 2025 base dividend is $1.00 per share, payable August 21, 2025.
Inspire Medical Systems reported second-quarter 2025 revenue of $217.1 million, up 11%, but posted a GAAP net loss of $3.6 million and cut its full-year 2025 revenue and diluted EPS guidance. Management said the U.S. launch of Inspire V is progressing slower than expected and the timeline for the full transition has been pushed out, which will affect results for the year. The filing also discloses that Executive Vice President Randall A. Ban will retire on January 30, 2026.
Q2 2025 revenue was $217.1 million, up from $195.9 million; GAAP net loss was $3.6 million, or $0.12 per share, versus net income of $9.8 million a year earlier.
2025 revenue guidance lowered to $900 million to $910 million from $940 million to $955 million; diluted EPS guidance lowered to $0.40 to $0.50 from $2.20 to $2.30.
Gross margin was 84.0% versus 84.8% a year earlier, including a $2.1 million charge for excess Inspire IV components inventory.
EVP Randall A. Ban notified the company on July 31, 2025 of his intent to retire on January 30, 2026.
SBA Communications reported second-quarter 2025 net income of $225.7 million, up from $159.5 million a year earlier, and raised its full-year 2025 outlook. AFFO per share fell 3.6% year over year to $3.17, and the company's reported profit gain included a $30.4 million currency-related gain on intercompany loans.
Q2 2025 net income was $225.7 million, or $2.09 per diluted share, versus $159.5 million, or $1.51, in Q2 2024.
AFFO per share was $3.17, down from $3.29 a year earlier; AFFO was $342.1 million versus $354.3 million.
Full-year 2025 AFFO per share outlook is $12.65 to $13.02, a $0.13 midpoint increase from the April 28, 2025 outlook.
On July 21, 2025, SBA agreed to sell its 369 Canadian towers for CAD$446.0 million, expected to close in Q4 2025; the board declared a $1.11 quarterly dividend payable September 18, 2025.
ZoomInfo reported second-quarter 2025 GAAP revenue of $306.7 million, up 5% year over year, and swung to GAAP net income of $24.0 million from a net loss a year earlier. The company raised its full-year 2025 GAAP revenue and adjusted EPS guidance and named interim CFO Graham O'Brien as permanent CFO effective August 1, 2025. Cash flow from operations fell 14% year over year, which shareholders may watch closely.
Q2 2025 GAAP revenue $306.7 million, up 5% year over year; GAAP net income $24.0 million, or $0.07 per diluted share, versus a net loss of $24.4 million in Q2 2024
FY 2025 GAAP revenue guidance raised to $1.215 billion to $1.225 billion from $1.195 billion to $1.205 billion; adjusted EPS guidance raised to $0.99 to $1.01 from $0.96 to $0.98
Michael Graham O'Brien named permanent CFO effective August 1, 2025, with a $470,000 base salary and a bonus target of 60% of base salary
Q2 cash flow from operations $108.9 million, down 14% year over year; unlevered free cash flow $99.9 million, down 17%
Simon Property Group reported second-quarter 2025 Real Estate FFO of $1.154 billion, or $3.05 per diluted share, up 4.1% from the prior year, and raised its full-year 2025 Real Estate FFO per share guidance to $12.45 to $12.65. Net income attributable to common stockholders for the first six months fell to $969.8 million from $1.225 billion, a period that included a large 2024 gain on equity interests.
Q2 2025 net income attributable to common stockholders was $556.1 million, or $1.70 per diluted share, versus $493.5 million, or $1.51, a year earlier.
Full-year 2025 Real Estate FFO per diluted share guidance raised to $12.45 to $12.65 from the prior outlook.
Board declared a third-quarter common dividend of $2.15 per share, up $0.10 or 4.9% year over year, payable September 30, 2025.
Six-month net income attributable to common stockholders was $969.8 million, or $2.97 per diluted share, compared with $1.225 billion, or $3.76, in 2024.
Tanger reported second-quarter 2025 diluted net income of $0.26 per share ($29.9 million), up from $0.22 a year earlier, and FFO of $0.58 per share ($68.6 million), up from $0.53. The company raised its full-year 2025 diluted FFO per share estimate to $2.24-$2.31 from $2.22-$2.30 and its diluted net income per share estimate to $0.93-$1.00 from $0.91-$0.99.
Q2 2025 diluted net income was $0.26 per share, or $29.9 million, versus $0.22 per share, or $24.6 million, in Q2 2024.
Q2 2025 FFO available to common shareholders was $0.58 per share, or $68.6 million, versus $0.53 per share, or $60.9 million.
2025 diluted FFO per share guidance is $2.24-$2.31, up from $2.22-$2.30.
Board authorized a quarterly dividend of $0.2925 per share, payable August 15, 2025 to holders of record on July 31, 2025.
V2X reported second-quarter 2025 revenue of $1.08 billion and net income of $22.4 million, compared with a net loss of $6.5 million a year earlier. The company raised its 2025 adjusted diluted EPS guidance and reaffirmed its revenue and adjusted EBITDA ranges, and it set up a $100 million share repurchase authorization.
Q2 revenue was $1.08 billion versus $1.07 billion a year earlier; net income was $22.4 million versus a net loss of $6.5 million.
Adjusted diluted EPS was $1.33, up 59% year over year; GAAP diluted EPS was $0.70.
A $100 million share repurchase authorization was established.
Allegiant reported second-quarter 2025 total operating revenue of $689.4 million, up 3.5% from a year earlier, but a GAAP net loss of $65.2 million, or $3.62 per diluted share, compared with earnings of $0.75 per share in the prior-year quarter. The loss reflects $103.3 million in net Sunseeker Resort special charges tied to the pending $200 million sale of the resort, and adjusted diluted EPS fell 30.5% to $1.23. The company also guided to an adjusted airline-only loss of $1.25 to $2.25 per share for the third quarter.
Q2 2025 GAAP diluted loss per share of $3.62, versus $0.75 earnings per share in Q2 2024
Q2 2025 adjusted diluted EPS of $1.23, down 30.5% from $1.77; adjusted airline-only operating margin of 8.6% versus 10.3%
Third-quarter 2025 guidance: adjusted airline-only EPS of ($1.25) to ($2.25); full-year adjusted airline-only EPS guided above $3.25
Sunseeker Resort sale for $200 million, subject to adjustments, expected to close in the third quarter
Dorman Products reported second-quarter 2025 net sales of $541.0 million, up 7.6% from a year earlier, and diluted EPS of $1.91, up 25%. The company raised its full-year 2025 guidance for net sales growth and diluted EPS, which is a positive signal for shareholders because both headline measures improved and the outlook was lifted.
Net sales were $541.0 million, up 7.6% from $503.0 million in the second quarter of 2024.
Diluted EPS was $1.91 versus $1.53; adjusted diluted EPS was $2.06 versus $1.67.
2025 net sales growth guidance rose to 7% to 9% from 3% to 5%; diluted EPS guidance rose to $8.05 to $8.35 from $7.00 to $7.30.
Management will hold a conference call and webcast on August 5, 2025, at 8:00 a.m. Eastern time.
HNI Corporation entered into a merger agreement on August 3, 2025, to acquire Steelcase Inc. Steelcase shareholders would receive $7.20 in cash and 0.2192 HNI shares for each share held, an implied $18.30 per share based on HNI's $50.62 closing price on August 1, 2025. HNI shareholders would own about 64% of the combined company, so the issuance of new HNI shares dilutes existing holders, and the deal is expected to close by the end of 2025 subject to shareholder and regulatory approvals.
Steelcase holders receive $7.20 cash plus 0.2192 HNI shares per share; implied value $18.30 per share at HNI's $50.62 close on August 1, 2025.
Total consideration to Steelcase common shareholders is about $2.2 billion; HNI holders would own about 64% of the combined company.
Run-rate cost synergies of $120 million are projected; the company expects the deal to be highly accretive to non-GAAP EPS beginning in 2027.
Closing requires approval by both HNI and Steelcase shareholders and regulatory clearances; either party may terminate if closing has not occurred by May 4, 2026, subject to extensions.
National Vision Holdings expanded its board to eleven directors and appointed Alex Wilkes to fill the new seat, effective August 1, 2025. The appointment follows a CEO succession plan first announced April 29, 2025, under which Reade Fahs becomes Executive Chairman and Wilkes succeeds him as CEO.
Board size increased by one director to a total of eleven, effective August 1, 2025
Alex Wilkes appointed to the Board effective August 1, 2025
Succession plan previously announced in April 29, 2025 Form 8-K: Reade Fahs to become Executive Chairman, Wilkes to succeed Fahs as CEO
Simmons First National Corporation said Chairman and CEO George Makris Jr. will retire at the end of 2025. Jay Brogdon, the company's president, will become president and CEO on January 1, 2026, and join the board, while Marty Casteel will become chairman. The filing does not describe changes to the company's financial results or outlook, and it says Brogdon's compensation information for his new role was not yet available.
George A. Makris Jr. (age 69) retires as chairman, director and CEO effective the end of December 31, 2025.
James "Jay" M. Brogdon (age 44) becomes president and CEO on January 1, 2026, and joins the board to fill Makris's seat.
Marty D. Casteel will succeed Makris as chairman effective January 1, 2026.
Brogdon will receive no separate pay for board service and will not immediately serve on board committees.
TG Therapeutics reported second quarter 2025 total revenue of $141.1 million, up from $73.5 million a year earlier, and net income of $28.2 million, compared with $6.9 million. The company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570 million to $575 million from $560 million, and its total global revenue target to approximately $585 million from $575 million.
Q2 2025 BRIUMVI U.S. net product revenue was $138.8 million, up 91% from the same period last year.
Full-year 2025 BRIUMVI U.S. net revenue target raised to $570 million to $575 million, from $560 million.
Full-year 2025 total global revenue target raised to approximately $585 million, from $575 million.
Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025.
On August 1, 2025, TDS and subsidiary Array completed the sale of Array's wireless operations and select spectrum assets to T-Mobile for an adjusted purchase price of about $4.3 billion, of which about $2.6 billion was cash and about $1.7 billion was paid through T-Mobile's exchange of Array notes. The deal also led to repayment of Array debt, a $23.00 per share special dividend declared by Array, and a master license agreement for Array towers, and the pro forma figures show the remaining business is far smaller than the reported results.
Adjusted purchase price about $4.3 billion: about $2.6 billion in cash and about $1.7 billion through exchange of Array notes
Array declared a $23.00 per share special dividend on August 1, 2025, payable August 19, 2025
Pro forma Q1 2025 operating revenues were $308 million versus $1,154 million as reported
Array's securitization facility was terminated July 31, 2025; bank facilities to be paid off effective August 4, 2025
Energizer reported fiscal third-quarter 2025 results for the period ended June 30, 2025, with net sales up 3.4% to $725.3 million and reported diluted EPS of $2.13, compared with a loss of $0.61 a year earlier. The company raised its full-year 2025 adjusted EPS outlook to $3.55 to $3.65, but the filing attributes much of the earnings gain to $112.4 million of production credits, and organic net sales grew only 0.1%.
Net sales were $725.3 million, up 3.4% from $701.4 million; organic net sales rose 0.1%.
Reported diluted EPS was $2.13 versus a loss of $0.61; adjusted EPS was $1.13 versus $0.79, with production credits of $112.4 million recorded in the quarter.
FY2025 adjusted EPS outlook was raised to $3.55 to $3.65; adjusted EBITDA is now expected at $630 to $640 million.
For the fourth quarter, adjusted EPS is expected at $1.05 to $1.15.
Bruker reported second quarter 2025 revenue of $797.4 million, down 0.4% from a year earlier, and non-GAAP diluted EPS of $0.32, down 38.5%. The company lowered its FY 2025 non-GAAP EPS guidance to $1.95 to $2.05 from the prior range implied by its outlook, citing weak demand in academic, biopharma and industrial markets, plus tariffs and currency pressure. Shareholders face lower near-term profit expectations, partly offset by a planned cost program of $100 million to $120 million in annual savings for FY 2026.
Q2 2025 revenue $797.4 million, down 0.4% yoy; organic revenue down 7.0%
Q2 2025 non-GAAP diluted EPS $0.32 vs. $0.52 a year earlier; GAAP diluted EPS $0.05
FY 2025 guidance: revenue $3.43 to $3.50 billion and non-GAAP EPS $1.95 to $2.05, compared with $2.41 in FY 2024
Cost savings initiative expected to reduce annual costs by $100 million to $120 million in FY 2026
Chemours, DuPont and Corteva agreed to a proposed Judicial Consent Order with the State of New Jersey to resolve pending environmental claims, including statewide PFAS claims. Chemours will pay 50% of the $875 million settlement over 25 years, about $250 million on a present value basis, and the settlement remains subject to notice, comment and court approval. Chemours also agreed to sell its rights to $150 million of potential PFAS insurance proceeds to DuPont and Corteva, which it expects to fully fund its settlement payments through at least 2030.
Settlement totals $875 million over 25 years, with pre-tax present value of about $500 million; payments begin no earlier than January 1, 2026
Chemours responsible for 50% of settlement payments, about $250 million on a present value basis
DuPont and Corteva to purchase Chemours' rights to $150 million of PFAS insurance proceeds, contingent on JCO approval
Settlement remains subject to notice and comment under New Jersey law and final court approval
Harley-Davidson's board appointed Arthur Starrs, current CEO of Topgolf, as President and CEO and a director effective October 1, 2025. Current CEO and Chairman Jochen Zeitz is retiring and resigning from the board on the same date, and director Troy Alstead will become Chairman; the filing does not report any financial results or guidance.
Arthur Starrs, 48, becomes President and CEO and a board member effective October 1, 2025; he has not yet been named to any board committee
Starrs' offer letter sets a $1,200,000 base salary, a 150% of salary target cash incentive beginning in 2026, and a $2,000,000 one-time cash award repayable if he resigns within 12 months
Starrs will receive a $4,500,000 one-time RSU award and a pro-rated 2025 RSU award valued at $1,625,000, plus annual LTIP grants valued at $6,500,000 beginning February 2026
Zeitz remains an employee as a Senior Advisor through February 2026 and says his retirement does not reflect any dispute with the Company
On August 3, 2025, DuPont, Chemours and Corteva agreed to a proposed judicial consent order with the State of New Jersey to resolve state claims over legacy contamination, including PFAS, subject to court approval. DuPont recorded a $177 million pre-tax charge in discontinued operations in the second quarter of 2025, reflecting the net present value of $311 million, which the filing estimates as its share of the settlement payments, so the settlement adds a large cost for shareholders.
Aggregate cash payment to New Jersey of $875 million, payable over 25 years and shared under the 2021 MOU among DuPont, Chemours and Corteva.
Second-quarter 2025 pre-tax charge of $177 million within discontinued operations; DuPont's estimated share of payments has a net present value of $311 million at an 8 percent discount rate.
DuPont and Corteva will establish a $475 million Reserve Fund, and DuPont will contribute $106.5 million of a $150 million NJ Escrow tied to Chemours' share of the settlement.
First annual payment due within 30 days of court entry, and no earlier than January 31, 2026; the settlement is subject to a public comment period and the company admits no liability.
Freshpet reported second-quarter 2025 net sales of $264.7 million, up 12.5%, and net income of $16.4 million, compared with a net loss of $1.7 million a year earlier. The company lowered its 2025 net sales growth forecast to 13% to 16% from 15% to 18%, cut its capital expenditure forecast to about $175 million from about $225 million, and removed its $1.8 billion 2027 net sales target, which matters to shareholders because it reduces the company's stated growth expectations.
Q2 2025 net sales were $264.7 million, up 12.5% from $235.3 million, with volume gains of 10.8%.
Q2 2025 net income was $16.4 million, or $0.33 per diluted share, versus a net loss of $1.7 million in the prior year period.
2025 net sales growth guidance was cut to 13% to 16%, from 15% to 18%; Adjusted EBITDA guidance of $190 million to $210 million was unchanged.
Capital expenditure guidance for 2025 was cut to about $175 million from about $225 million, and the 2027 net sales target of $1.8 billion was removed.
IDEXX Laboratories reported second-quarter 2025 revenue of $1,109 million, up 11% as reported and 9% organic, and diluted EPS of $3.63, up 49% as reported. The company raised its full-year 2025 revenue guidance to $4,205 million–$4,280 million and its EPS outlook to $12.40–$12.76, which shareholders will weigh against a prior-year litigation accrual that depressed the comparison base.
Q2 2025 revenue $1,109 million, up 11% as reported and 9% organic; comparable EPS $3.50, up 17%
Diluted EPS $3.63 included $0.07 from a discrete tax reserve release and $0.10 from share-based compensation tax benefits
2025 revenue guidance raised to $4,205 million–$4,280 million, up $90 million at midpoint; EPS outlook raised by $0.40 at midpoint to $12.40–$12.76
Waters reported second-quarter 2025 sales of $771 million, up 9% as reported and 8% in constant currency, and non-GAAP EPS of $2.95, up 12% from $2.63 a year earlier. The company raised its full-year 2025 non-GAAP EPS guidance to $12.95 to $13.05 and its constant currency sales growth guidance to +5.5% to +7.5%, which points to stronger expected results for shareholders. The release also says the company is integrating a proposed combination with BD Biosciences & Diagnostic Solutions.
Q2 2025 sales were $771 million, up 9% as reported and 8% in constant currency, versus $709 million in Q2 2024.
GAAP diluted EPS was $2.47, compared with $2.40 a year earlier; non-GAAP EPS was $2.95, compared with $2.63.
Full-year 2025 non-GAAP EPS guidance was raised to $12.95 to $13.05, and constant currency sales growth guidance to +5.5% to +7.5%.
Third-quarter 2025 non-GAAP EPS is expected to be $3.15 to $3.25.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.